ARCHIVES

Phase III Trial Retrospective Analysis Finds Talimogene Laherparepvec Reduced Tumors

This article is from The Cancer Letter archive.

Vol. 37 No. 3 | March 28, 2014

Download PDF Visit The Full Archive

Related Articles

CCRAC Calls for New Comp Center, Community Hospital Core Grants For Control Development

August 24, 1979

Nature Editorial Criticizes NCI PR Spending

March 15, 2013

NCI Issues 8 Awards, 12 Feasibility Grants, In New SPORE Program

October 9, 1992

Trial In Metastatic Disease To Be Unblinded After Regorafenib Meets Primary Endpoint

November 25, 2011

NIH begins transition to electronic grant submissions; seeks comment on options for NRSA funding.

October 28, 2005

DRCCA Completes New Cancer control Research Guidelines

August 5, 1983